Deals
A 30-Year Quest For Alzheimer's Remedy Nears The Finish Line
- TauRx will soon unveil human trial results for its drug LMTX
- Singapore company's backers include Genting Berhad and Temasek
Claude Wischik.
Source: University of AberdeenThis article is for subscribers only.
After decades of researching a treatment for Alzheimer’s, Claude Wischik is set to find out whether his lonely 30-year battle can lead to one of the first real treatments for the memory-destroying brain disorder that afflicts millions worldwide.
The co-founder of Singapore-based TauRx Pharmaceuticals Ltd. plans to present results from ongoing final human trials on its experimental Alzheimer’s drug, LMTX, as early as July. An earlier study showed that patients given the company’s treatment had better cognitive scores than those who didn’t get it, according to research it published in the Journal of Alzheimer’s Disease.